Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creon after total pancreatectomy for pancreatic exocrine insufficiency
2024-512798-29-00Phase 3Authorised
- Sponsor
- Meda
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of pancrelipase in exocrine pancreatic insufficiency (EPI), sponsored by Meda. Primary endpoint: Percentage of patients treated with higher than approved final treatment doses. Planned start Jan 2025; status: authorised.
02
Drugs
pancrelipase
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on 2024-512798-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512798-29-00.